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Abstract
Background: Isoniazid preventive therapy is a key public health intervention for the prevention of tuberculosis
disease among people living with HIV. Despite the confirmed efficacy of isoniazid preventive therapy and global
recommendations existing for decades, its implementation remains limited. In resource constrained settings, few
have investigated why isoniazid preventive therapy is not implemented on full scale. This study was designed to
investigate the level of isoniazid preventive therapy implementation and reasons for suboptimal implementation in
Tigray region of Ethiopia.
Methods: A review of patient records combined with a qualitative study using in-depth interviews and focus group
discussions was conducted in 11 hospitals providing isoniazid preventive therapy in the Tigray Region. The study
participants were health providers working in the HIV clinics of the 11 hospitals in the province. Health providers
were interviewed about their experience of providing isoniazid preventive therapy and challenges faced during its
implementation. All conversations were audio-recorded. Record review of 16,443 HIV patients registered for care in
these hospitals between September 2011 and April 2014 was done to determine isoniazid preventive therapy
utilization. Data were collected from April to August 2014.
Results: Fifty health providers participated in the study. Overall isoniazid preventive therapy coverage of the region
was estimated to be 20 %. Isoniazid stock out, fear of creating isoniazid resistance, problems in patient acceptance,
and lack of commitment of health managers to scale up the program were indicated by health providers as the
main barriers hindering implementation of isoniazid preventive therapy.
Conclusion: Implementation of isoniazid preventive therapy in Tigray region of Ethiopia had low coverage.
Frequent interruption of isoniazid supplies raises the concern of interrupted therapy resulting in creation of
isoniazid resistance. Health managers, drug suppliers and partners working in HIV and tuberculosis programs should
be committed to ensure an uninterrupted supply of isoniazid and full scale implementation of isoniazid preventive
therapy to eligible people living with HIV.
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Background
Tuberculosis (TB) preventative therapy for people living
with HIV (PLHIV) is necessary and an important public
health intervention especially in developing countries
where both TB and HIV are serious problems and
known to be synergistic and bidirectional. The World
Health Organization (WHO) recommends the use of at
least six months Isoniazid preventive therapy (IPT) for
PLHIV without active TB in countries with a high bur-
den of TB infection [1]. Ethiopia is classified as one of
the world’s high TB burden, high multi-drug resistant-
TB burden and high TB-HIV burden country by WHO
[2]. IPT implementation in the country started in 2005
[3]. Per national guidelines, all PLHIV should be
screened for active TB disease using the WHO four-
symptom based screening (current cough, fever, night
sweats or weight loss). If no evidence of active TB is
found, IPT should be provided [1, 3].
Many studies demonstrated the benefit of IPT among
PLHIV [3–11]. A Cochrane review of 12 randomized
controlled trials revealed that IPT lowers the incidence
of active TB compared to placebo (relative risk 0.68,
95 % confidence interval (CI) 0.54 to 0.85) [3]. Recent
studies in Ethiopia reported a reduction of about 50 % in
tuberculosis incidence in patients using IPT [5, 6]. Des-
pite the confirmed efficacy of IPT and existing global
recommendations and policy by the WHO since 2004,
its implementation remains limited. Globally, the num-
ber of PLHIV who were treated with IPT reached 933
000 in 2014, an increase of about 60 % compared with
2013 [2, 12]. Nonetheless, 77 % of countries did not re-
port provision of IPT as part of HIV care in 2014.
The implementation guideline for TB/HIV collabora-
tive activities in Ethiopia states that IPT can be given to
PLHIV after screening for the absence of four TB sug-
gestive symptoms (current cough, fever, night sweats
and weight loss) and any contraindications [3]. To those
for whom active TB is excluded, a daily, self-
administered dose of isoniazid is given for a period of
six months at a dose of 5 mg/kg for children and
300 mg/day for adults. IPT can be initiated before or
after the initiation of antiretroviral therapy. In Ethiopia,
the number of PLHIV newly enrolled in care who initi-
ated IPT in 2014 was 10,385 (excluding the missing data
for 3 of Ethiopia’s 11 regions) [12]. A study by Cowan et
al. [13] reported low IPT implementation in the Tigray
region of Ethiopia.
Different reasons have been pointed out for the low
uptake of IPT implementation globally. These are
amongst others, related to health service providers’
knowledge and perception about IPT provision, inad-
equate application of the symptom screening tool (inten-
sified TB case finding) to rule out active TB, inadequate
patient adherence to IPT and fear of amplifying
resistance to isoniazid through IPT [12–17]. In Ethiopia
limited evidence is available regarding the status of and
barriers to IPT implementation. As IPT coverage is
known to be limited, it would be important to determine
the actual level of IPT implementation and the reasons
for its low uptake.
Methods
This study was conducted in Tigray region located in
northern Ethiopia. This study setting was selected to fur-
ther investigate the reports by Cowan et al. [13] which
indicated low uptake of IPT implementation in the re-
gion. As per the 2014 health status report, the region
had 102 health facilities providing care to PLHIV [18].
In the region, IPT was initiated late in the year 2010.
Eleven public hospitals, offering IPT for at least three or
more years were included in this study. A further three
newly established hospitals as well as all the health cen-
ters in the region were not included as these health facil-
ities were not providing IPT yet as per unpublished
reports obtained from the Tigray regional health bureau.
A mixed approach of quantitative and qualitative study
designs was employed. The quantitative section aimed to
determine IPT coverage of the region while in-depth in-
terviews and focus group discussions were used to inves-
tigate barriers for health workers to implement IPT. The
quantitative data were collected by using a structured
data collection form and review of patient records. Infor-
mation on availability of isoniazid, functionality of x-ray
machine, stock out of reagents and slides required for
the diagnosis of TB was collected from each hospital. In-
formation on the number of PLHIV registered in HIV
care and provided with IPT between September 2011
and April 2014 was collected from IPT registries of each
hospital. IPT coverage was determined as percentage of
PLHIV started on IPT among all PLHIV registered in
HIV care.
Health providers (physicians, nurses, health officers,
pharmacy workers and laboratory staff ) were the inter-
viewees and all participated in the focus group discus-
sions. Health providers who were present during the
time of the visit of the field team to the 11 hospitals and
having at least 5 months working experience in HIV care
were included in the qualitative study. The study partici-
pants were approached with the assistance of the trained
study focal person in each hospital, selected and trained
to collect data. The focal persons were recruited among
nurses and pharmacists working in the 11 hospitals but
not in the HIV clinic. The focal persons were trained as
data collectors on how to approach study participants,
how to ask for informed consent, conduct interviews
and focus groups, collect quantitative data from patient
records while maintaining the confidentiality of the col-
lected data. The in-depth-interviews and focus groups
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were conducted in a separate room in each hospital
close to the HIV clinic to ensure privacy. Each inter-
viewee was first asked individually about his/her experi-
ence of providing IPT and challenges faced in its
implementation. This was then followed by a focus
group discussion to identify common barriers hindering
implementation of IPT. Each in-depth interview took
about 25 min while focus groups had an average dur-
ation of about 35 min till saturation was reached. The
focus group discussions were moderated by the investi-
gators. All the planned in-depth interviews in the 11
hospitals (three to five interviews in each hospital) were
conducted. A total of 8 representative focus groups were
conducted (one focus group per hospital) till saturation
was reached. Data were collected between April and
August, 2014.
Data from both quantitative and qualitative parts were
analyzed by the investigators. The quantitative data were
analyzed using SPSS for windows version 20 statistical
software. Data was checked for completeness and accur-
acy through proofreading while entering the data into
the software. Descriptive statistics (frequencies and per-
centage) were employed and data were visualized using
tables and bar graphs. Audio-recorded data from the in–
depth interviews and focus groups were transcribed
using verbatim and translated into English. Qualitative
data verification for accuracy and completeness was
done through reading and re-reading by different inves-
tigators to ensure all recorded information and varia-
tions were identified. After transcription, codes were
developed by two investigators based on the original
terms used, and were matched. The transcripts and
notes were analyzed thematically by categorizing them
in line with the specific objectives (providers, patient,
and resource requirement related barriers for implemen-
tation of IPT). The codes were presented, discussed and
checked within the research team. Tentative categories
and sub-categories were created from the clustered
codes, and subsequently main themes emerged based on
the patterns and relationships between the categories.
Main themes were illustrated with representative
quotations.
Results
Fifty health providers participated in the qualitative
study. The mean age (±SD) of health providers was 31
(±6) years. Twenty four (48 %) of the participants were
nurses. Thirty (60 %) of health providers had more than
two years working experience in HIV care (Table 1).
All the 11 hospitals reported having a functional chest
x-ray machine. Four hospitals (36.4 %) reported at least
once a stock out in the past one year of microscopic re-
agents and/or slides for the diagnosis of TB. In the year
2013, shortage of adult and pediatric dose of isoniazid
was reported in seven and four of the 11 hospitals re-
spectively. This resulted in interruption of IPT among
PLHIV already on IPT and limited initiation of IPT for
new PLHIV.
Out of the 16,443 PLHIV registered in the HIV clinics
between September 2011 and April 2014, 3230 (19.6 %)
had initiated IPT and 68 % of them had documentation
on completion of six month IPT (Fig. 1). Despite the
adoption of IPT policy in the country since 2005, health
facilities included in this study started implementation
in the years 2010 to 2012. IPT coverage varied between
hospitals; two hospitals had high IPT coverage (of 47.0 %
and 36.2 %) while two other hospitals had a much lower
coverage (of 8.1 % and 9.2 %). Also, four of the 11 hospi-
tals were not providing IPT at the time of the study due
to isoniazid stock outs. The shortage had been experi-
enced since about two months; some PLHIV already on
IPT were forced to discontinue their treatment. Besides
interrupting treatment for those on IPT, it limited initi-
ation of IPT for new PLHIV. Low IPT coverage was
more seen among the facilities that started IPT imple-
mentation late, in 2012 (Table 2).
Challenges in IPT implementation
Irregularity of isoniazid supply and fear of drug resistance
Although most providers believed that IPT can be effect-
ive, multiple factors had impeded implementation of IPT
in the region. Most concerns raised were about the un-
reliable provision of isoniazid causing fear of isoniazid
resistance. This was raised as a concern by almost all
health providers during all focus groups as illustrated by
the following quotes:
‘One time they (regional administrators) say go ahead,
next time shortage happens after patients take for two
Table 1 Demographic characteristics of health providers
interviewed at 11 HIV clinics of Tigray, Northern Ethiopia, 2014
Demographic characteristics Health providers (N = 50)
N %
Age (yrs) <30 25 50.0
30–60 25 50.0
Sex Female 21 42.0
Male 29 58.0
Profession Nurse 24 48.0
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or three months. Many patients are stopping it
without completion. We can’t be sure of the continuity
of supply that is why we usually hesitate to initiate
new ones’ –health officer
One participant emotionally said ‘I don’t know! Are we
helping or hurting our patients? There is irregular
supply of isoniazid. It was the first phase patients who
completed 6 month treatment. The others had
interruptions after taking two or three months. This
may lead to isoniazid resistance’ –doctor
‘…despite the current availability of sufficient isoniazid,
there are some reservations in initiating IPT for new
patients due to fear of future stock outs’ –pharmacist
‘Since I started working in this hospital, I had never
provided IPT. Either there is no medication or it’s
insufficient to our clients. We have strong fear of
resistance development. Stock out is a common
problem in our hospital’ –health officer
‘…we start today the interruption follows tomorrow.
I believe the risk of resistance may outweigh its
benefit. Our patients are also losing trust in us.
When we told them (the patients) the medication is
not available, they feel as they might be exposed to
danger’ –nurse
‘It is not easy to identify those patients who need IPT.
There could be missed opportunities. Providing this
Fig. 1 Number of PLHIV provided with IPT in 11 hospitals of Tigray, Northern Ethiopia, September 2011- April 2014







Number of PLHIV on IPT at the time
of study




Hospital 1 2012 1734 0 159 9.2
Hospital 2 2012 1386 75 201 14.5
Hospital 3 2012 1320 58 159 12.0
Hospital 4 2012 1094 19 515 47.0
Hospital 5 2010 3229 0 634 19.6
Hospital 6 2011 1460 43 529 36.2
Hospital 7 2012 1327 45 108 8.1
Hospital 8 2012 954 0 142 14.9
Hospital 9 2011 776 6 186 24.0
Hospital 10 2012 1843 60 188 10.2
Hospital 11 2011 1320 0 409 31.0
Total 16,443 306 3, 230 19.6
PLHIV people living with HIV, IPT isoniazid preventive therapy
aIPT coverage was calculated by dividing the number of PLHIV registered in a particular health facility to the total number of PLHIV provided IPT
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single drug on top of the stock outs, obviously
resistance may develop’ -doctor
‘We sent drug susceptibility test for patients with
presumed multi-drug resistant TB and they become
isoniazid resistant. I always question if the isoniazid
we are providing for prophylaxis is contributing to
such resistance. We hesitate in initiation. Unless it’s
supported by data, it’s difficult to say IPT is being
beneficial … –health officer
‘Previously there were problems of awareness in most of
us (exposure of patients to a single drug isoniazid may
lead to resistance). But currently there is no such fear as
far as we are treating latent TB. And the problems of
on-off supply are currently corrected’ –pharmacist
Policy implementation gaps
There are gaps between having the IPT policy in place
and the actual implementation. The policy for IPT
among PLHIV implementation was adopted nationally
and implementation started in Ethiopia since 2005; how-
ever, the participants report that the policy was only im-
plemented in Tigray region since 2011 due to fear of
amplifying resistance to isoniazid through IPT. Health
authorities’ concern regarding isoniazid resistance in the
region still exists due to irregularities in the drug supply.
Not all HIV clinics in the region were permitted by the
regional health authorities to offer IPT. At the time of
this study, health centers providing antiretroviral therapy
were not permitted to offer IPT, IPT was only being of-
fered in hospitals. Lack of commitment of the health au-
thorities and drug supply irregularities were raised by
the service providers as reasons for the gap between
having a policy and actual implementation. Health ser-
vice providers also reported poor monitoring and lack of
supervision of the IPT program by higher managers.
The following quotes illustrate the above interpretation.
‘IPT is a sensitive issue in this region because one time
the region was refusing its use and was criticized as the
only region not implementing. One time I remember the
regional health authorities refusing its use unless there
is continuous supply from pharmaceutical fund and
supply agency (PFSA) …’ -nurse
‘We ask isoniazid every two months from PFSA. But
most of the time they had stock outs. I think there is a
problem in the system. Priority should be given to
PLHIV…’ –pharmacist
‘…IPT is not being considered as prime treatment for
PLHIV as antiretroviral therapy and cotrimoxazole.
This is mainly the problem of the government and
suppliers. If we can convince our patients that IPT will
help them and the government is committed to supply
isoniazid, it is possible to prevent tuberculosis in our
patients’ –pharmacist
‘Previously IPT was not being provided to our patients.
Now we have started it. There are problems of
commitment from responsible bodies. We ourselves
didn’t push others as such for its implementation. I
believe we don’t have a problem of supply, it’s due to
lack of giving attention for the program. There are
problems of convincing its’ importance to our patients.
There are also problems of following the
implementation by higher authorities. IPT should be
considered as prime issue’ –health officer
Drug side effect, pill burden and adherence related barriers
Providers reported that the unavailability of the adult
dose of isoniazid resulted in a pill burden for PLHIV as
instead of one, three tablets of the pediatric doses were
provided to adults. This was compromising overall ad-
herence. Most providers indicated that they prescribed
IPT based on the patients’ willingness and they indicated
patients’ were unwilling to add isoniazid to the antiretro-
viral therapy due to fear of having many pills.
‘Sometimes it’s only the 100 mg isoniazid lefts in our
stock. Providing three tablets for an adult is resulting
in pill burden. Patients complain having many
medications, and some gastrointestinal irritations.
Hence, some patients are not willing to take it’ –
pharmacist
‘We had two patients who developed TB while on IPT.
Such cases could be either a missed one during
screening or due to immune reactivation in a patient
with a low CD4 count or it could be because of patient
non-adherence…’ –doctor
Side effects such as gastrointestinal irritation, periph-
eral neuropathy and hepatotoxicity were also mentioned
as challenges in IPT implementation. Some of the side
effects are preventable however unavailability of pyridox-
ine had contributed to the problem of neuropathy.
‘…there is also shortage of pyridoxine. This could lead
to increased risk of peripheral neuropathy…’ –
pharmacist
‘We had patients who interrupted the treatment due
to shortage. Even currently we are not providing it. Its
implementation is poor. It’s only initiation, we never
see a patient completing it. There is a big problem in
supply. There are also some patients who interrupted
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IPT due to side effects such as hepatotoxicity and
peripheral neuropathy’ –nurse
Lack of training and guidelines
Health providers also reported the absence of training
opportunities as well as availability of guidelines with
regards to IPT. They believed that training should be
provided first before the introduction of a program and
it should be continued thereafter after for new staffs.
‘We did not take special training regarding IPT. We
have been trained within the antiretroviral therapy
package and we don’t have special guideline…’ –nurse
‘Training and update on IPT are lacking. I had never
seen a new guideline, which are important to make us
more confident’ –health officer
‘Also we are not trained in this regard. It was by letter
they (regional health authorities) told us to start IPT’
–nurse
The main barriers to IPT implementation underpin-
ning the current research are summarized in a concep-
tual framework (Fig. 2).
Discussion
Implementation of IPT in the Tigray region of Ethiopia
was started late and coverage was limited despite the
fact that the policy has been in place in the country
since 2005 [3]. The barriers hindering implementation of
the IPT program were predominantly related to isonia-
zid supply problems, patient acceptance, concerns about
amplifying resistance to isoniazid through IPT, and lack
of commitment of health managers to scale up its
implementation.
In this study only about one fifth (20 %) of PLHIV reg-
istered in care were provided with IPT. This is lower
than the reported IPT coverage of around 30 % for Addis
Ababa in 2011 [19, 20]. Differences in access to isoniazid
could have contributed to the lower coverage observed
in the northern region of Tigray as supply could have
been better in Addis Ababa, the capital city of Ethiopia.
Another reason for this difference could be related to
the denominator used. In our study, IPT coverage was
determined with all PLHIV registered in the HIV clinics
as denominator, whereas the Addis Ababa studies calcu-
lated the coverage with the eligible as denominator this
excluding those illegible to receive IPT. Our study was
based on retrospective data, and eligibility of IPT could
not be determined from the available routine records for
all PLHIV therefore we adopted the wider denominator.
Despite this difference, both results still indicate sub op-
timal coverage as the WHO target level of 50 % coverage
[12] is not yet achieved.
The main barrier leading to sub-optimal implementa-
tion of IPT observed in this study was shortage of iso-
niazid. It seems that lack of effective systems to manage
drug supply is impeding implementation of the policy.
Shortage of essential drugs, such as drugs used for TB
and HIV treatment and prevention has been reported as
a problem in health facilities of Ethiopia [21–24].
Fig. 2 Conceptual framework of barriers to implementation of IPT among PLHIV in Tigray, Northern Ethiopia, 2011–2014
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Non-availability of isoniazid was also observed by
Getahun et al. [12] as a barrier to global IPT imple-
mentation. The supply problem of isoniazid could
arise at the level of quantification, procurement, and/
or distribution. Participants in this study complained
that they do not receive the quantities they requested.
A study from Addis Ababa reported that only 47 %
of the health facilities received the full quantity of
drugs they ordered [24].
The success of IPT implementation is mainly
dependent on continuous resource mobilization, cap-
acity building and monitoring. Health providers per-
ceived that insufficient attention is being given to IPT by
responsible bodies. Most of the hospitals in this study
started implementing the IPT program just because they
were told do so by higher officials. In some hospitals
sensitization workshops, technical trainings, and oper-
ational guidelines were not provided. Health care staff
also felt that there was no adequate monitoring and
evaluation of the policy implementation. Similarly a
study in Addis Ababa [16] reported that lack of
reinforcement by health officials and stakeholders work-
ing in TB was affecting implementation of the IPT pol-
icy. A study in South Africa also reported lack of
awareness on the benefits of IPT and the guidelines and
recommendations by prescribers as primary barrier to
IPT implementation [17]. Provision of a clear up-to-date
policy and provision of trainings has been found to im-
prove IPT implementation in other studies [25–27].
Trainings and good communication are vital for proper
understanding of the policy and avoid ambiguities on
IPT provision among health providers. This study did
not include regional health managers, therefore their
perspective is missing.
Lack of confidence in excluding active TB and fear of
resistance development has been a matter of debate for
many years [28, 29]. The WHO strongly argues that
concerns regarding the development of isoniazid resist-
ance should not be a barrier for providing IPT [1] as the
evidence disproves the development of isoniazid-
resistant TB after providing IPT to PLHIV [28, 30].
However, fear of isoniazid resistance is still a challenge
to IPT implementation. In settings with limited diagnos-
tic capacity, concerns about resistance may arise when
use of chest X-ray is considered important to exclude ac-
tive TB disease [31]. Concerns regarding amplifying re-
sistance to isoniazid through IPT have been pointed out
as challenge in several other studies [12, 17, 26, 32, 33].
Low completion rates of IPT were observed in this
study. The main reasons could be related to shortage of
isoniazid, poor patient adherence and side effects. Un-
availability of adult isoniazid dose resulted in pill burden
when providers instead issued three tablets of the
pediatric doses to make up the adult dose. This resulted
in unwillingness of patients to take IPT due to a concern
of having too many tablets. And in those willing to take
it, patient adherence was questionable due to the pill
burden. A comparable study in Addis Ababa [16] also
observed that poor patient adherence was a major bar-
rier affecting the implementation of IPT. Concerns re-
garding pill burden and inadequate patient adherence
were also raised in other studies [12, 15, 34]. In this
study peripheral neuropathy and hepatotoxicity were re-
ported as potential side effects related to IPT resulting
in some patients discontinuing the treatment. Providers
perceived that lack of pyridoxine in the hospitals in-
creased the prevalence of peripheral neuropathy. A study
by Durovni et al. [27] reported that 1.2 % of persons ini-
tiating IPT discontinued therapy due to adverse reac-
tions. However, the rate of hepatotoxicity associated
with isoniazid was reported as low (0.001–0.15 %) in
several studies [9, 12, 33, 35].
The current study provides insight into the main
reasons underlying health providers’ reluctance to
offer IPT like fear of resistance development due to
frequent interruption of IPT, lack of clients’ willing-
ness to take isoniazid, and uncertainties on the future
supply of the drug. Concerns about resistance devel-
opment through IPT had been disproved in previous
studies. However, these studies were done with full
supply of IPT and without any interruption. In the
current study the concern of frequent interruption of
IPT supply was a big challenge for the IPT program.
Future studies should focus on the risk of isoniazid
resistance development through IPT in settings with
irregular supplies and frequent interruption of IPT.
Finally, this study determined the actual coverage of
IPT but also gained insight in teasing out the under-
lying factors, some of them have been observed in
other studies. Key factor here is the drug supply issue
which is fixable and concrete actions can be taken.
Conclusions
Implementation of IPT in the Tigray region of Ethiopia
was low with only one fifth of PLHIV covered. The main
barrier mentioned hindering IPT implementation was ir-
regular supply of isoniazid resulting in stock outs and
interruption of IPT provision, creating fear among
health care workers for development of drug resistance.
Health managers, drug suppliers and partners working
in HIV-TB programs should be committed to ensure an
uninterrupted isoniazid supply for the success of IPT
implementation.
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